-+ 0.00%
-+ 0.00%
-+ 0.00%

ORYZON ANNOUNCES AUTHORIZATION IN SPAIN OF VIVALDI, A COLLABORATIVE CLINICAL STUDY WITH CETLAM TO EVALUATE IADADEMSTAT IN COMBINATION WITH STANDARD-OF-CARE THERAPY IN HIGH-RISK NEWLY-DIAGNOSED AML SUBPOPULATIONS

Reuters·11/03/2026 13:00:05

Please log in to view news